We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




GE to Acquire Amersham for $9.5 Billion

By Biotechdaily staff writers
Posted on 14 Oct 2003
Immediately following the closing of its Instrumentarium acquisition, the General Electric Company (Waukesha, WI, USA) has agreed to buy Amersham plc (Little Chalfont, UK) for US$9.5 billion in stock.

Upon completion of the acquisition, Sir William Castell, CEO of Amersham, will become vice chairman and member of the board of General Electric. More...
He will also become CEO of the combined GE and Amersham medical businesses, to be called GE Healthcare Technologies, which will be based in the United Kingdom. Joseph Hogan, senior vice president of General Electric, will continue to lead the GE medical business.

Amersham Health (Little Chalfont, UK) is a global leader in diagnostic imaging agents, while Amersham Biosciences (Piscataway, NJ, USA) performs protein separations and develops instruments and software for research. Both segments are designed to advance GE's strategy of addressing high-growth segments of the healthcare industry. Amersham was formed in 1997 by the mergers of Amersham International (UK), Pharmacia Biotech (Sweden), and Nycomed (Norway). By adding these high-technology platforms to its diagnostic imaging, healthcare services, and information technology businesses, GE hopes to position the company to participate in new developments in molecular imaging and personalized medicine.

"GE and Amersham will be an exciting combination of talents, businesses, and technologies,” said Jeffrey R. Immelt, chairman and CEO of GE. "Amersham's diagnostic pharmaceutical and life sciences business will add new, high-growth platforms to GE Medical's diagnostic imaging, services, and healthcare information technology businesses.”




Related Links:
GE
Amersham

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Clinical Informatics Platform
CLARION™
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.